SPONSORSHIP OPPORTUNITIES

Take advantage of our sponsorship opportunities to ensure your company is front and center at the 2023 Innovation Night.

**Gallery Sponsor: $37,000  Exclusive Opportunity**

Goods & Services: $3,600*

**Sponsor benefits of Innovation Night include all benefits of Lead Sponsorship plus:**

- 20 tickets to attend Innovation Night
- 20 tickets to use throughout the 2023/24 Season (subject to availability)
- Two designated individuals will be invited to join the Innovation Night host committee
- Invitation for 10 to attend the exclusive Sponsor Party

**Lead Sponsor: $27,000**

Goods & Services: $3,000*

**Sponsor benefits and recognition include all benefits of Host Sponsorship plus:**

- 20 tickets to attend Innovation Night
- 12 tickets to use throughout the 2023/24 Season (subject to availability)
- Invitation for 8 to attend the exclusive Sponsor Party

**Host Sponsor: $16,000**

Goods & Services: $2,350*

**Sponsor benefits and recognition include all benefits of Co-Host Sponsorship plus:**

- 16 tickets to attend Innovation Night
- 10 tickets to use throughout the 2023/24 Season (subject to availability)
- Invitation for 6 to attend the exclusive Sponsor Party

**Co-Host Sponsor: $8,000**

Goods & Services: $1,300*

**Sponsor benefits and recognition include:**

- Corporate logo and Co-Host Sponsor recognition on all event collateral
- Social media promotion, featuring your company on Facebook, Instagram, Twitter & LinkedIn
- Opportunity for a premium display in the Innovation Gallery at the event (500 impressions)
- 10 tickets to attend Innovation Night
- 4 tickets to use throughout the 2023/24 Season (subject to availability)
- One designated individual will be invited to join the Innovation Night host committee
- Invitation for 4 to attend the exclusive Sponsor Party

*Fair Market Values: Innovation Night Package = $100/per unit; 2023/24 Season ticket = $75/per unit; Social Media Promotion = $100

In addition to the benefits and visibility at Innovation Night on October 2, 2023, all corporate sponsors will enjoy these Corporate Circle benefits throughout the 2023/24 Season:

- Logo recognition on the Potiker Theatre Corporate Sponsors signage (100,000+ impressions)
- Logo included in all six theatre programs on the Corporate Sponsors page (100,000+ impressions)
- Logo and link on the Corporate Sponsors page of LaJollaPlayhouse.org
- 20% corporate discount on tickets for La Jolla Playhouse productions
- Opportunity to host a pre-show event for your guests in one of our spaces (additional fees and restrictions apply)
MONDAY, OCTOBER 2, 2023
At La Jolla Playhouse | 5:30pm - 8:30pm
Elegant cocktail reception for 500+ C-level executives and guests with delicious cuisine and an open bar. Plus, an Innovation Night gallery featuring interactive exhibits from leading San Diego companies and delightful Without Walls-inspired theatre to enjoy.

WHY INNOVATION NIGHT?
As a leader in innovation onstage, La Jolla Playhouse couldn’t be a better place to host this extraordinary event each year, bringing San Diego’s flourishing community of science and technology innovators together for an evening of creative exchange. Over the past fifteen years, Innovation Night has raised well over $2 million to help enhance the Playhouse’s own “R&D” efforts – including our signature play development programs, Without Walls (WOW) series of immersive and site-inspired theatre, as well as ongoing artist commissions and residencies – all while facilitating partnerships among artists and leaders in San Diego’s life sciences, biotech, high-tech, clean-tech and defense and telecommunication industries.

HONORING IRWIN JACOBS, SC.D.

Founding Chairman and CEO Emeritus, Qualcomm

Dr. Jacobs received his B.S. in electrical engineering from Cornell University in 1956 and his S.M. and Sc.D. degrees in Electrical Engineering from MIT in 1957 and 1959. He was a faculty member in Electrical Engineering at MIT from 1959 to 1966, and a Professor of Computer Science and Engineering at UC San Diego from 1966 to 1972. While at MIT, he coauthored Principles of Communication Engineering, the first textbook on digital communications and information theory.

In 1968, Jacobs co-founded Linkabit Corporation, progressing from consulting services to become a major supplier of digital communication equipment for government and industry. It was selected by ARPA (now DARPA) to develop SATNET to extend the ARPANET to Europe. In 1977, SATNET was one of three networks used in the first live demonstration of the Internet protocol. Industry-first products developed and manufactured by Linkabit included the dual-modem satellite terminal for the Air Force, based on what was later named reduced instruction set processing (RISC), the VideoCipher encrypted satellite-to-home TV system initially for HBO and later industry-wide, and the very-small-aperture satellite terminal (VSAT) business communication system initially for Schlumberger but then commercialized and adopted by Walmart, 7-Eleven, and many gasoline stations for credit card transactions. He sold Linkabit to M/A-Com in 1980, remaining as board member and executive vice-president until April 1985.

With six others from Linkabit, he co-founded Qualcomm July 1, 1985, serving as Chairman and CEO until retiring as CEO in 2005 and Chairman in 2008. Under his leadership, Qualcomm pioneered CDMA technology for the cellular industry, first commercially deployed in Hong Kong in 1995 and in South Korea and the United States in 1996. These second generation (2G) networks initially utilized handsets manufactured in San Diego by Qualcomm. Because CDMA supports efficient voice and mobile wideband internet access, it became the underlying technology for all third-generation (3G) cellular networks, serving billions of subscribers. Qualcomm led the industry in the transition to fourth generation (4G) LTE and now is leading the transition to fifth generation (5G). It licenses its technology worldwide and is among the largest suppliers to global manufacturers of integrated circuits for mobile devices.

Jacobs is a member and past chairman of the National Academy of Engineering, a member of the American Academy of Arts and Sciences, the American Philosophical Society, the National Inventors Hall of Fame, and a Fellow of the IEEE, American Association for the Advancement of Science, and the Computer History Museum. From 2006 to 2016, he was Board Chair of the Salk Institute for Biological Studies and for 10 years served on the Advisory Board of the School of Economics and Management at Tsinghua University in Beijing.

Jacobs has received many awards and honors, including the National Medal of Technology (1994), the James Clerk Maxwell Award, the IEEE Alexander Graham Bell Medal Award, the Dorothy I. Height Chair’s Award, of the Leadership Council on Civil Rights, the Franklin Institute Bower Award for Business Leadership, the Marconi Prize, the IEEE Medal of Honor, the Carnegie Medal of Philanthropy with his wife Joan, and the IMEC Lifetime of Innovation Award. He is the recipient of 11 honorary doctorates and delivered the 2005 commencement address at MIT.

Dr. Jacobs and his wife Joan are active philanthropists and founding signers of the Giving Pledge. They have been major supporters of La Jolla Playhouse – where Joan has been involved in Board leadership for nearly four decades – as well as the UC San Diego Jacobs School of Engineering, the UCSD Jacobs Medical Center, the Jacobs Technion-Cornell Innovation Institute, the San Diego Symphony, the San Diego Central Library, the Jacobs-Cushman Food Bank, Second Chance in San Diego, the Museum of Contemporary Art, the High Tech High Charter School System, and the Jacobs Institute for Innovation in Education at the University of San Diego. They annually support fellowships and scholarships for students at UCSD, Cornell, MIT, the Technion, and three New Bedford High Schools. In June 2022 they were honored by the Young Concert Artists at Carnegie Hall.
Denise Bevers, President and CEO, VETmAb Biosciences

As a biotech executive and advisor, Denise has led companies to explosive business growth and raised approximately $500 million in capital both privately and publicly, in addition to bringing life-saving veterinary and human therapeutics to market. Denise is President and CEO of VETmAb Biosciences, a veterinary biopharmaceutical company developing monoclonal antibody (or “mAb”) therapeutics for dogs and cats. Prior to founding VETmAb Bio, Denise served as the COO of DTx Pharma, a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease. To date, Denise is most proud of her tenure as President and COO of Kindred Biosciences, a veterinary biopharmaceutical company she co-founded in 2012, took public in 2013, and sold to Elanco in 2021. Prior to KindredBio, Denise served as President and Founding Partner of SD Scientific, a full-service medical affairs and communications company, and has held management positions at Elan Pharmaceuticals, SkyPharma, Quintiles, and Scripps Clinic and Research Foundation. Denise is a passionate trustee, executive committee member, and Secretary of La Jolla Playhouse. She also serves on the board of several nonprofits and biotech companies, from CONNECT, which helps innovators and entrepreneurs in Southern California by providing access to investors, mentors, and education, to Hilltop Bio, a Boston-based biotech developing regenerative therapies for animals. Denise earned her B.S. from University of California, San Diego in Ecology, Behavior, and Evolution and holds an M.B.A. from Keller Graduate School of Management. Denise and her husband, Lon, love spending time with their dogs, as well as enjoying live music and travel. They are passionate supporters of theater, both locally and as Broadway investors.

Tim Scott, President and CEO, AustinPx

Mr. Scott is President and CEO of AustinPx, a technology company enhancing the pharmacokinetics of critical medicines. He is the co-founder and Executive Board Chair of TEQA Therapeutics, a glycobiology company focused on lysosomal storage disorders and recombinant heparin sulfates. He previously was co-founder and President of Pharmatek Laboratories, a contract development and manufacturing company (sold to Catalent Pharma Solutions in 2016). Prior to that, he was Senior Vice President at Active.com (IPO 2011). Mr. Scott serves on the Board of Avellas, a bioscience company working to create better outcomes for cancer patients with its activatable cell-penetrating peptide technology. He also serves on the board of DTx, a biotechnology company using fatty acid motifs to deliver RNA therapeutics. He previously served on the board of Zacharon Pharmaceuticals (sold to Biomarin 2014). Mr. Scott has founded or supported multiple spinouts from UC San Diego including Zacharon, TEGA, LipoNexus, Knoubis Bio, Nerio and Augment. Mr. Scott is immediate past Executive Board Chair of CONNECT, a non-profit organization helping to create and scale innovation companies in San Diego. He serves as Chair of BIOCOM, a non-profit organization supporting the needs of bio/pharma companies in California. Mr. Scott serves on the Medical Research Advisory Committee for the Conrad Prebys Foundation, providing grants to innovative research in the health sciences. At UC San Diego, he serves on the Dean’s Advisory Council for the Division of Biological Sciences. In the community, Mr. Scott is a trustee for the La Jolla Playhouse, a Tony-award winning regional theatre. And he serves on the board of Outside the Lens, a non-profit providing photography and digital media programs for underserved youth. Mr. Scott earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.

2023 INNOVATION NIGHT HOST COMMITTEE
THANK YOU TO THOSE WHO HAVE ALREADY SECURED SPONSORSHIP:

PRESENTING SPONSOR
PNC BANK

FOUNDING SPONSOR
Cooley

LEAD SPONSOR
UC San Diego

HOST SPONSORS
The Lodge at Torrey Pines Qualcomm

CO-HOST SPONSORS

IN-KIND SPONSORS

List as of August 3, 2023

ABOUT LA JOLLA PLAYHOUSE
With 33 Broadway transfers, 108 world premieres and a Tony Award for The Rich Family Artistic Director, Christopher Ashley, La Jolla Playhouse is where artists and audiences come together to create what’s new and next in American Theatre. It is our mission to advance theatre as an art form, telling stories that inspire empathy and create a dialogue toward a more just future. With our intrepid spirit and eclectic, artist-driven approach we will continue to cultivate a local, national and global following with an insatiable appetite for audacious work.

For more information, please contact James Skeet, Corporate Relations Manager
Email: jskeet@ljp.org | Phone: (858) 228-3078
Mail: La Jolla Playhouse, PO Box 12039, La Jolla, CA 92039

LaJollaPlayhouse.org/innovation-night